MCID: ACR014
MIFTS: 50

Acral Lentiginous Melanoma malady

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Acral Lentiginous Melanoma

About this section

Aliases & Descriptions for Acral Lentiginous Melanoma:

Name: Acral Lentiginous Melanoma 10 45 12
Acral Lentiginous Malignant Melanoma of Skin 45
Acral Lentiginous Melanoma, Malignant 10
Acral Lentiginous Malignant Melanoma 65
 
Malignant Acral Lentiginous Melanoma 10
Palmar/plantar Melanoma 45
Subungual Melanoma 45
Alm 45

Classifications:



External Ids:

Disease Ontology10 DOID:6367
UMLS65 C0346037

Summaries for Acral Lentiginous Melanoma

About this section
Disease Ontology:10 A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes.

MalaCards based summary: Acral Lentiginous Melanoma, also known as acral lentiginous malignant melanoma of skin, is related to alstrom syndrome and melanoma, and has symptoms including macule An important gene associated with Acral Lentiginous Melanoma is NRAS (Neuroblastoma RAS Viral Oncogene Homolog), and among its related pathways are Thyroid cancer and MAP2K and MAPK activation. Affiliated tissues include skin, prostate and endothelial, and related mouse phenotypes are limbs/digits/tail and craniofacial.

Wikipedia:68 Acral lentiginous melanoma is a kind of lentiginous skin melanoma. Melanoma is a potentially serious... more...

Related Diseases for Acral Lentiginous Melanoma

About this section

Diseases related to Acral Lentiginous Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 100)
idRelated DiseaseScoreTop Affiliating Genes
1alstrom syndrome11.2
2melanoma11.1
3eccrine papillary adenocarcinoma10.5KIT, NRAS
4malignant fibroxanthoma10.4KIT, NRAS
5corticosterone methyloxidase deficiency10.4KIT, NRAS
6rad21-related cornelia de lange syndrome10.4BRAF, NRAS
7head and neck carcinoma10.4KIT, NRAS
8gallbladder leiomyosarcoma10.4KIT, NRAS
9lacrimal passage granuloma10.4KIT, NRAS
10non-langerhans-cell histiocytosis10.4BRAF, NRAS
11gastrointestinal carcinoma10.4CDKN2A, NRAS
12bowing of legs, anterior with dwarfism10.4CDKN2A, TERT
13gastrointestinal neuroendocrine tumor10.4CDKN2A, NRAS
14benign mesothelioma10.3CDKN2A, KIT
15follicular basal cell carcinoma10.3CDKN2A, KIT
16mixed liposarcoma10.3CDKN2A, KIT
17nerve root neoplasm10.3BRAF, KIT
18posterior mediastinum cancer10.3BRAF, KIT
19cervical ribs, sprengel anomaly, anal atresia, and urethral obstruction10.3CDKN2A, TERT
20splenogonadal fusion limb defects micrognatia10.3BRAF, CDKN2A
21pancreatic ductal adenocarcinoma10.2CDKN2A, NRAS
22cervical large cell neuroendocrine carcinoma10.2CDKN2A, KIT
23fibrosarcoma10.2CDKN2A, KIT
24sarcoma10.2
25primary malignant melanoma of the cervix10.2CDKN2A, PTEN
26acantholytic squamous cell skin carcinoma10.2CDKN2A, KIT
27autosomal dominant medullary cystic kidney disease with hyperuricemia10.2CDKN2A, PTEN
28childhood cerebral astrocytoma10.2PTEN, TERT
29desmoplastic infantile astrocytoma10.1CDKN2A, KIT
30bronchitis10.1BRAF, PTEN
31cervical verrucous carcinoma10.1CDKN2A, PTEN
32childhood pilocytic astrocytoma10.1CDKN2A, PTEN
33malignant giant cell tumor of soft parts10.1MET, NRAS
34angiokeratoma of mibelli10.1CDKN2A, KIT
35primary syphilis10.1MET, TERT
36psoriatic arthritis10.0
37multiple myeloma10.0
38arthritis10.0
39myeloma10.0
40tinea pedis10.0
41basal cell carcinoma10.0
42laryngitis10.0
43tuberculosis10.0
44clear cell sarcoma10.0
45tinea nigra10.0
46lichen planus10.0
47lentigo maligna melanoma10.0
48lichen planus pigmentosus10.0
49organ system benign neoplasm10.0CDKN2A, NRAS
50juvenile astrocytoma10.0CDKN2A, PTEN

Graphical network of the top 20 diseases related to Acral Lentiginous Melanoma:



Diseases related to acral lentiginous melanoma

Symptoms for Acral Lentiginous Melanoma

About this section

UMLS symptoms related to Acral Lentiginous Melanoma:


macule

Drugs & Therapeutics for Acral Lentiginous Melanoma

About this section

Drugs for Acral Lentiginous Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DabrafenibapprovedPhase 27044462760, 44516822
Synonyms:
BRAF inhibitor GSK2118436
Dabrafenib
Dabrafenib Mesylate
 
GSK2118436
GSK2118436a
Tafinlar
dabrafenib
2
Dasatinibapproved, investigationalPhase 2268302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
 
Dasatinibum
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
dasatinib
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
3
TrametinibapprovedPhase 2111871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
4
Sunitinibapproved, investigationalPhase 2486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
5
Maleic acidexperimentalPhase 2274110-16-7444972, 444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
6Imatinib MesylatePhase 2577123596
7Protein Kinase InhibitorsPhase 23162
8
CediranibPhase 2879933475
Synonyms:
288383-20-0
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
790713-41-6
AKOS005145767
AZD 2171
AZD-2171
AZD2171
AZD2171, Recentin, Cediranib
CHEMBL491473
CID9933475
 
Cediranib
Cediranib (USAN/INN)
Cediranib maleate
D08881
EC-000.2328
Kinome_3318
M6294
NSC-732208
Recentin
S1017_Selleck
UNII-NQU9IPY4K9
ZD-2171
cediranib
9Cyclin-Dependent Kinase Inhibitor ProteinsPhase 220
10Contraceptives, OralPhase 23734
11Angiogenesis InhibitorsPhase 23688
12Angiogenesis Modulating AgentsPhase 23611
13tyrosineNutraceuticalPhase 2596
14
Ganciclovirapproved, investigationalPhase 114082410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene IV
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir Sodium
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3
15Nucleic Acid Synthesis InhibitorsPhase 13836
16Ganciclovir triphosphatePhase 1140
17Antiviral AgentsPhase 18071
18Anti-Infective AgentsPhase 117220

Interventional clinical trials:

(show all 13)
idNameStatusNCT IDPhase
1AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaCompletedNCT00243061Phase 2
2Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00470470Phase 2
3A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has SpreadRecruitingNCT01395121Phase 2
4Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryRecruitingNCT00700882Phase 2
5Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaRecruitingNCT02083354Phase 2
6SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaActive, not recruitingNCT00577382Phase 2
7Dinaciclib in Treating Patients With Stage IV MelanomaActive, not recruitingNCT00937937Phase 2
8Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaActive, not recruitingNCT01120275Phase 2
9Imatinib in Patients With Mucosal or Acral/Lentiginous MelanomaActive, not recruitingNCT00424515Phase 2
10Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaActive, not recruitingNCT00788775Phase 2
11Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged MelanomaTerminatedNCT01092728Phase 2
12Gene Therapy and Ganciclovir in Treating Patients With Stage IV MelanomaCompletedNCT00005057Phase 1
13Study of Families With MelanomaRecruitingNCT00445783

Search NIH Clinical Center for Acral Lentiginous Melanoma

Genetic Tests for Acral Lentiginous Melanoma

About this section

Anatomical Context for Acral Lentiginous Melanoma

About this section

MalaCards organs/tissues related to Acral Lentiginous Melanoma:

33
Skin, Prostate, Endothelial, T cells, B cells, Neutrophil, Monocytes

Animal Models for Acral Lentiginous Melanoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Acral Lentiginous Melanoma:

38 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053718.7KIT, MET, NRAS, PTEN
2MP:00053828.5BRAF, KIT, MET, NRAS
3MP:00011868.5BRAF, CDKN2A, KIT, NRAS, PTEN
4MP:00107718.5BRAF, CDKN2A, KIT, NRAS, PTEN
5MP:00053898.3BRAF, CDKN2A, KIT, PTEN, TERT
6MP:00053888.0BRAF, CDKN2A, KIT, MET, PTEN
7MP:00053907.9BRAF, CDKN2A, KIT, PTEN, TERT
8MP:00053697.8BRAF, CDKN2A, KIT, MET, PTEN
9MP:00028737.7BRAF, KIT, MET, NRAS, PTEN, TERT
10MP:00053807.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN
11MP:00053707.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN
12MP:00053917.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN
13MP:00053867.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN
14MP:00036317.4BRAF, CDKN2A, KIT, MET, PTEN, TERT
15MP:00053977.3BRAF, CDKN2A, KIT, NRAS, PTEN, TERT
16MP:00053797.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
17MP:00020067.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
18MP:00053857.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
19MP:00053817.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
20MP:00053847.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
21MP:00053767.0BRAF, CDKN2A, KIT, MET, NRAS, PTEN
22MP:00107686.9BRAF, CDKN2A, KIT, MET, NRAS, PTEN
23MP:00053786.9BRAF, CDKN2A, KIT, MET, NRAS, PTEN
24MP:00053876.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN

Publications for Acral Lentiginous Melanoma

About this section

Articles related to Acral Lentiginous Melanoma:

(show top 50)    (show all 116)
idTitleAuthorsYear
1
Amelanotic acral lentiginous melanoma mimicking diabetic ulcer: a challenge to diagnose and treat. (26679765)
2016
2
Acral Lentiginous Melanoma. (26601870)
2016
3
Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? (25455840)
2015
4
Reflectance confocal microscopy features of acral lentiginous melanoma: a comparative study with acral nevi. (26428577)
2015
5
The distribution pattern of HMB-45-positive cells is helpful for the diagnosis of early acral lentiginous melanoma in situ. (25773399)
2015
6
Reconstruction of large wounds using a combination of negative pressure wound therapy and punch grafting after excision of acral lentiginous melanoma on the foot. (26173565)
2015
7
Screening for Acral Lentiginous Melanoma in Dark-Skinned Individuals. (26083954)
2015
8
TERT promoter mutation is uncommon in acral lentiginous melanoma. (24588324)
2014
9
Recurrent acral lentiginous melanoma in situ suggesting the field cell theory. (25473243)
2014
10
Comparison of dermatoscopic images of acral lentiginous melanoma and acral melanocytic nevus occurring on body weight-bearing areas. (25396085)
2014
11
Acral lentiginous melanoma of the toe treated using Mohs surgery with sparing of the digit and subsequent reconstruction using split-thickness skin graft. (22931051)
2013
12
Psoriatic arthritis with acral lentiginous melanoma: role for methotrexate? (24249911)
2013
13
Popliteal sentinel lymph node biopsy is important in malignant melanoma of the distal lower extremities: a case report of acral lentiginous melanoma with simultaneous inguinal and popliteal lymph node micrometastases. (22157852)
2012
14
Acral junctional nevus versus acral lentiginous melanoma in situ: a differential diagnosis that should be based on clinicopathologic correlation. (21732773)
2011
15
The "spaghetti technique": an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). (21167406)
2011
16
Acral lentiginous melanoma. (21549241)
2011
17
Comparison of secondary intention healing and full-thickness skin graft after excision of acral lentiginous melanoma on foot. (21615605)
2011
18
Acral lentiginous melanoma in situ: a diagnostic and management challenge. (24281086)
2010
19
Cutaneous involvement in multiple myeloma mimicking acral-lentiginous melanoma. (20466190)
2010
20
Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. (18758972)
2009
21
Progression from Acral Lentiginous Melanoma in situ to Invasive Acral Lentiginous Melanoma. (20523783)
2009
22
Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. (19380664)
2009
23
Expression of p16 protein in acral lentiginous melanoma. (20415670)
2009
24
Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature. (18822168)
2008
25
Dermoscopy identifies histopathologically indiscernible malignant lesion of atypical melanosis of the foot, an early lesion of acral lentiginous melanoma in situ. (18384603)
2008
26
Constitutive activation of the phosphatidyl inositol 3 kinase signalling pathway in acral lentiginous melanoma. (17999703)
2008
27
Acral lentiginous melanoma: histopathological prognostic features of 121 cases. (17596173)
2007
28
Acral lentiginous melanoma misdiagnosed as verruca plantaris: a case report. (17083858)
2006
29
Acral lentiginous melanoma: an immunohistochemical study of 20 cases. (12709000)
2003
30
Acral-lentiginous melanoma. (10881468)
2000
31
An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma. (10657449)
2000
32
Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. (10754493)
2000
33
Acral lentiginous melanoma. (9879051)
1998
34
Plantar flap reconstruction for acral lentiginous melanoma. (9367024)
1997
35
Acral lentiginous melanoma of the palm. (9136165)
1996
36
Acral lentiginous melanoma. (8328633)
1993
37
Acral lentiginous melanoma associated with Down's syndrome. (8482754)
1993
38
Acral lentiginous melanoma: case studies from Kauai. (1428854)
1992
39
Ganglioside expression of human melanoma and tumor progression. Ganglioside composition of a plaque and a nodule of acral lentiginous melanoma. (1409417)
1992
40
The current management and prognosis of acral lentiginous melanoma. (1642394)
1992
41
Subungual basal cell carcinoma versus acral lentiginous melanoma. (3655030)
1987
42
Pigmented freckles on the sole of acral lentiginous melanoma in situ. (3908530)
1985
43
Acral lentiginous melanoma: an illustrative case report and brief review of the literature. (6498406)
1984
44
Acral lentiginous melanoma simulating "clear cell sarcoma of tendon and aponeuroses". (6863685)
1983
45
Acral lentiginous melanoma and lentigo maligna occurring in Werner's syndrome. (6627991)
1983
46
Acral lentiginous melanoma in situ. (7122752)
1982
47
Acral lentiginous melanoma of the penis. (7075635)
1982
48
Dermatology-epitomes of progress: acral lentiginous melanoma. (18748764)
1981
49
Acral lentiginous melanoma. (7389397)
1980
50
A darkly pigmented lesion of a great toe (acral lentiginous melanoma). (864073)
1977

Variations for Acral Lentiginous Melanoma

About this section

Cosmic variations for Acral Lentiginous Melanoma:

7 (show top 50)    (show all 60)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM460BRAFskin,acral,malignant melanoma,acral lentiginous19
2COSM476BRAFskin,acral,malignant melanoma,acral lentiginous19
3COSM562NRASskin,acral,malignant melanoma,acral lentiginous19
4COSM580NRASskin,acral,malignant melanoma,acral lentiginous19
5COSM583NRASskin,acral,malignant melanoma,acral lentiginous19
6COSM584NRASskin,acral,malignant melanoma,acral lentiginous19
7COSM1255KITskin,acral,malignant melanoma,acral lentiginous19
8COSM1257KITskin,acral,malignant melanoma,acral lentiginous19
9COSM1290KITskin,acral,malignant melanoma,acral lentiginous19
10COSM1304KITskin,acral,malignant melanoma,acral lentiginous19
11COSM18682KITskin,acral,malignant melanoma,acral lentiginous19
12COSM29015KITskin,acral,malignant melanoma,acral lentiginous19
13COSM235682KITskin,acral,malignant melanoma,acral lentiginous19
14COSM1166809PTENskin,acral,malignant melanoma,acral lentiginous19
15COSM1430154KITskin,acral,malignant melanoma,acral lentiginous19
16COSM565NRASskin,subungual,malignant melanoma,acral lentiginous14
17COSM563NRASskin,sole,malignant melanoma,acral lentiginous13
18COSM1138BRAFskin,sole,malignant melanoma,acral lentiginous13
19COSM33972KITskin,hand,malignant melanoma,acral lentiginous13
20COSM110724BAP1skin,sole,malignant melanoma,acral lentiginous13
21COSM1651643KITskin,sole,malignant melanoma,acral lentiginous13
22COSM467BRAFskin,acral,malignant melanoma,NS12
23COSM521KRASskin,NS,malignant melanoma,acral lentiginous12
24COSM564NRASskin,NS,malignant melanoma,acral lentiginous12
25COSM566NRASskin,NS,malignant melanoma,acral lentiginous12
26COSM569NRASskin,acral,malignant melanoma,NS12
27COSM573NRASskin,NS,malignant melanoma,acral lentiginous12
28COSM577NRASskin,NS,malignant melanoma,acral lentiginous12
29COSM1219KITskin,acral,malignant melanoma,NS12
30COSM1273KITskin,acral,malignant melanoma,NS12
31COSM1321KITskin,acral,malignant melanoma,NS12
32COSM27639BRAFskin,NS,malignant melanoma,acral lentiginous12
33COSM29529RB1skin,NS,malignant melanoma,acral lentiginous12
34COSM33966KITskin,acral,malignant melanoma,NS12
35COSM36305KITskin,acral,malignant melanoma,NS12
36COSM107839GRIN2Askin,NS,malignant melanoma,acral lentiginous12
37COSM107986GRIN2Askin,NS,malignant melanoma,acral lentiginous12
38COSM133755KITskin,acral,malignant melanoma,NS12
39COSM133756KITskin,acral,malignant melanoma,NS12
40COSM133757KITskin,acral,malignant melanoma,NS12
41COSM133760KITskin,acral,malignant melanoma,NS12
42COSM133762KITskin,acral,malignant melanoma,NS12
43COSM133763KITskin,acral,malignant melanoma,NS12
44COSM133765KITskin,acral,malignant melanoma,NS12
45COSM133767KITskin,acral,malignant melanoma,NS12
46COSM133769KITskin,acral,malignant melanoma,NS12
47COSM133774KITskin,acral,malignant melanoma,NS12
48COSM133780KITskin,acral,malignant melanoma,NS12
49COSM144512KITskin,NS,malignant melanoma,acral lentiginous12
50COSM144520KITskin,acral,malignant melanoma,NS12

Expression for genes affiliated with Acral Lentiginous Melanoma

About this section
Search GEO for disease gene expression data for Acral Lentiginous Melanoma.

Pathways for genes affiliated with Acral Lentiginous Melanoma

About this section

Pathways related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 28)
idSuper pathwaysScoreTop Affiliating Genes
19.6BRAF, NRAS
29.6BRAF, NRAS
39.6BRAF, NRAS
49.6BRAF, NRAS
5
Show member pathways
9.2BRAF, KIT, NRAS
69.1CDKN2A, NRAS, TERT
7
Show member pathways
9.1BRAF, CDKN2A, NRAS
89.1BRAF, CDKN2A, NRAS
9
Show member pathways
9.0BRAF, NRAS, PTEN
108.8BRAF, CDKN2A, PTEN
118.8BRAF, MET, NRAS
12
Show member pathways
8.5BRAF, KIT, NRAS, PTEN
13
Show member pathways
8.5BRAF, MET, PTEN
14
Show member pathways
8.5BRAF, MET, PTEN
158.4BRAF, CDKN2A, NRAS, PTEN
16
Show member pathways
8.3BRAF, KIT, MET, NRAS
17
Show member pathways
8.3BRAF, KIT, MET, NRAS
188.2KIT, MET, NRAS, PTEN
198.2KIT, MET, NRAS, PTEN
208.1CDKN2A, MET, NRAS, PTEN
21
Show member pathways
8.1BRAF, MET, NRAS, PTEN
22
Show member pathways
8.1BRAF, MET, NRAS, PTEN
23
Show member pathways
8.1BRAF, MET, NRAS, PTEN
24
Show member pathways
7.7BRAF, KIT, MET, NRAS, PTEN
25
Show member pathways
7.6BRAF, CDKN2A, MET, NRAS, PTEN
26
Show member pathways
7.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
277.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
28
Show member pathways
6.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN

GO Terms for genes affiliated with Acral Lentiginous Melanoma

About this section

Biological processes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1myeloid progenitor cell differentiationGO:000231810.2BRAF, KIT
2somatic stem cell divisionGO:004810310.1CDKN2A, KIT
3regulation of axon regenerationGO:004867910.0BRAF, PTEN
4somatic stem cell population maintenanceGO:003501910.0BRAF, KIT
5replicative senescenceGO:00903999.8CDKN2A, TERT
6activation of MAPKK activityGO:00001869.5BRAF, KIT, NRAS
7vascular endothelial growth factor receptor signaling pathwayGO:00480109.5BRAF, KIT, NRAS
8insulin receptor signaling pathwayGO:00082869.5BRAF, KIT, NRAS
9regulation of protein stabilityGO:00316479.4CDKN2A, PTEN, TERT
10long-term synaptic potentiationGO:00602919.2BRAF, PTEN
11fibroblast growth factor receptor signaling pathwayGO:00085439.0BRAF, KIT, NRAS, PTEN
12neurotrophin TRK receptor signaling pathwayGO:00480119.0BRAF, NRAS, PTEN
13axon guidanceGO:00074118.8BRAF, KIT, MET
14innate immune responseGO:00450878.5BRAF, KIT, NRAS, PTEN
15signal transductionGO:00071658.0BRAF, KIT, MET, NRAS

Sources for Acral Lentiginous Melanoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet